Resalis Therapeutics is focused on developing innovative RNA-based therapies to address complex metabolic disorders, particularly obesity and metabolic associated fatty liver disease (MAFLD). Their lead candidate, RES-010, is a non-coding RNA drug designed to inhibit the microRNA miR-22, which has been identified as a significant regulator of lipid metabolism. Elevated levels of miR-22 have been linked to various metabolic disorders, and preclinical studies have shown that inhibiting this microRNA can protect against obesity and fatty liver disease, as well as reverse fat accumulation in affected animals. This foundational research supports the potential of RES-010 as a first-in-class therapy with a disease-modifying impact.

The company is pursuing a dual indications strategy with RES-010, targeting both obesity and MAFLD, including its progressive state, metabolic associated steatohepatitis (MASH). Resalis Therapeutics is advancing RES-010 through clinical evaluation, with plans for a Clinical Trial Application (CTA) submission targeted for 2024. Their approach leverages a deep understanding of non-coding RNAs and their biological roles, positioning Resalis as a key player in the evolving landscape of metabolic disease treatment.

Italy

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease.

The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.

Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

Resalis Therapeutics

Company Details